Roth Capital Comments on Enovis' FY2025 Earnings (NYSE:ENOV)

Enovis Co. (NYSE:ENOV - Free Report) - Equities research analysts at Roth Capital lowered their FY2025 earnings per share (EPS) estimates for Enovis in a research note issued to investors on Thursday, February 27th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $3.24 per share for the year, down from their prior forecast of $3.31. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis' FY2026 earnings at $3.74 EPS.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million.

Separately, Needham & Company LLC decreased their target price on Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday.

Enovis Price Performance

Enovis stock traded down $0.82 during mid-day trading on Friday, hitting $37.83. The company's stock had a trading volume of 1,653,938 shares, compared to its average volume of 1,013,966. Enovis has a twelve month low of $37.60 and a twelve month high of $63.96. The stock's fifty day moving average price is $44.72 and its two-hundred day moving average price is $44.28. The stock has a market capitalization of $2.15 billion, a P/E ratio of -17.27 and a beta of 1.94. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Institutional Investors Weigh In On Enovis

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Enovis by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after purchasing an additional 75,348 shares during the period. Diamond Hill Capital Management Inc. grew its holdings in shares of Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock valued at $129,352,000 after buying an additional 218,660 shares in the last quarter. DAVENPORT & Co LLC grew its holdings in shares of Enovis by 6.0% during the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after buying an additional 157,216 shares in the last quarter. Royce & Associates LP lifted its stake in Enovis by 2.8% in the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after acquiring an additional 66,891 shares in the last quarter. Finally, State Street Corp boosted its position in Enovis by 4.3% during the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company's stock worth $70,913,000 after acquiring an additional 68,190 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.